Home / Business / Recommended Mix Momentum Stocks: Concho Resources (NYSE:CXO), AstraZeneca (NYSE:AZN)

Recommended Mix Momentum Stocks: Concho Resources (NYSE:CXO), AstraZeneca (NYSE:AZN)

Concho Resources, Inc. (NYSE:CXO) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.33% to close at $137.20 with the total traded volume of 1.18 Million shares. Concho Resources Inc. (CXO) completed its before reported acquisition of about 40,000 net acres in the core of the Midland Basin from Reliance Energy for about $1.625 billion.

The takeoverd assets, which are located in Andrews, Martin and Ector counties in Texas, include production of 10 MBoepd, comprised of 67% crude oil. Concho is presently running one rig on the takeoverd assets and plans to add a second rig in early 2017. The firm has institutional ownership of 92.80%, while insider ownership included 0.10%. Its price to sales ratio ended at 12.27. CXO attains analyst recommendation of 1.90 with week performance of 11.64%.

AstraZeneca PLC (NYSE:AZN) [Trend Analysis] moved down reacts as active mover, shares a decrease -1.30% to traded at $32.57 and the percentage gap among open changing to regular change was -0.09%. AstraZeneca PLC (AZN) reported top-line results from the EUCLID trial which included 13,885 patients in 28 countries.

The firm stated Brilinta (ticagrelor) did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease patient population and therefore did not meet the primary endpoint of the trial. Sean Bohen, Chief Medical Officer at AstraZeneca, stated: “The proven benefits of Brilinta in acute coronary syndrome and post-myocardial infarction patients are established and remain unchanged. We are disdesignated that the EUCLID trial results showed Brilinta did not demonstrate a benefit over clopidogrel in this specific symptomatic PAD population.”

The firm’s current ratio calculated as 0.90 for the most recent quarter. The firm past twelve months price to sales ratio was 3.41 and price to cash ratio remained 17.66. As far as the returns are concern, the return on equity was recorded as 13.90% and return on investment was 11.50% while its return on asset stayed at 3.70%. The firm has total debt to equity ratio measured as 1.30.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Check Also

Stocks Retreat on New Development: Deutsche Bank (NYSE:DB), Ingram Micro (NYSE:IM)

Shares of Deutsche Bank AG (NYSE:DB) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease …

Leave a Reply

Your email address will not be published. Required fields are marked *